New Data Show Treatment with Lilly’s Neutralizing Antibodies Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV016) Together Reduced Risk of COVID-19 Hospitalizations and Death by 70 Percent
The Pharma Data
JANUARY 26, 2021
Lilly’s chief scientific officer and president of Lilly Research Laboratories. However, as with any such undertaking, there are substantial risks and uncertainties in the process of drug research, development and commercialization. Bamlanivimab FDA Approval History. have reached record highs.
52 
Let's personalize your content